Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by Over 40% in Phase 3 Trial

A new mRNA vaccine tailored to each patient's tumor has reduced the risk of melanoma recurrence by more than 40 percent, according to Phase 3 trial results. The findings were reported by WIRED. Because the vaccine is customized to the individual tumor, it represents a personalized approach to cancer treatment. The results add to growing evidence that mRNA vaccine technology may be effective against cancer. The article presents these trial outcomes as a further sign of the technology's potential in oncology.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.




Discussion (0)
Log in to join the discussion and vote.
Log in